Free Trial
NASDAQ:VANI

Vivani Medical Q2 2025 Earnings Results & Report

Vivani Medical logo
$0.98 -0.15 (-12.97%)
Closing price 11/12/2026 04:00 PM Eastern
Extended Trading
$0.98 -0.01 (-0.85%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vivani Medical missed analyst earnings expectations in its Q2 2025 results, released August 13, 2025. The company reported EPS of -$0.12 versus the -$0.10 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
12:00 AM ET

Vivani Medical EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.10
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Vivani Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vivani Medical Q2 2025 Earnings FAQ

Vivani Medical (NASDAQ:VANI) reported earnings of -$0.12 per share for Q2 2025, missing the consensus estimate of -$0.10. The report was announced on Wednesday, August 13, 2025.

Vivani Medical Earnings Headlines

URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
Vivani Nears Key Data Readout For Obesity Implant
See More Vivani Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vivani Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivani Medical and other key companies, straight to your email.

About Vivani Medical

Vivani Medical (NASDAQ:VANI) is a clinical-stage biopharmaceutical company developing miniature, subcutaneous drug implants designed to provide continuous delivery of medicines over extended periods. Its proprietary NanoPortal technology is intended to address challenges associated with conventional dosing, including frequent injections, daily administration and inconsistent medication adherence.

The company’s development programs have focused primarily on therapies for metabolic diseases. Its NPM-115 program is designed to deliver exenatide for chronic weight management, while NPM-119 is intended to provide continuous exenatide delivery for the treatment of type 2 diabetes. Vivani has also pursued additional implantable programs involving therapies such as semaglutide for obesity and related metabolic conditions.

Vivani Medical is based in the United States and is led by President and Chief Executive Officer Adam Mendelsohn, Ph.D. As an emerging biotechnology company, Vivani’s product candidates remain subject to clinical development and regulatory review, and the company’s programs may change as research progresses.

View Vivani Medical Profile